Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.23.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities    
Net loss $ (16,247) $ (12,270)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization expense 612 24
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan 2,817 3,537
Stock-based compensation - PAVmed Inc. 2014 Equity Plan 391 298
Change in fair value - Senior Secured Convertible Note 789
Loss on issue and offering costs - Senior Secured Convertible Note 1,186
APA-RDx: Issue common stock - settle termination payment 713
Changes in operating assets and liabilities:    
Accounts receivable (10) 111
Prepaid expenses and other current assets (275) 168
Accounts payable (431) 1,958
Accrued expenses and other current liabilities 743 285
Due To: PAVmed Inc. - operating expenses, employee related costs, MSA Fee 2,667 113
Net cash flows used in operating activities (7,045) (5,776)
Cash flows from investing activities    
Purchase of equipment (17) (148)
Net cash flows used in investing activities (17) (148)
Cash flows from financing activities    
Proceeds – issue of preferred stock 13,625
Proceeds – issue of Senior Convertible Note, net of offering cost 9,925
Proceeds – issue of common stock – At-The-Market Facility 284
Proceeds – exercise of stock options 187
Proceeds – issue common stock – Employee Stock Purchase Plan 276
Net cash flows provided by financing activities 24,110 187
Net increase (decrease) in cash 17,048 (5,737)
Cash, beginning of period 22,474 53,656
Cash, end of period $ 39,522 $ 47,919